Siu-Hin Wan1, Paul M McKie1, John A Schirger1, Joshua P Slusser2, David O Hodge2, Margaret M Redfield1, John C Burnett1, Horng H Chen3. 1. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota. 2. Department of Health Sciences Research, Mayo Clinic and Foundation, Rochester, Minnesota. 3. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota; Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota. Electronic address: chen.horng@mayo.edu.
Abstract
OBJECTIVES: This study determined whether there is development of tachyphylaxis to enhancement of cardiorenal response to acute volume loading (AVL) with B-type natriuretic peptide (BNP) after 12-week, twice-daily subcutaneous BNP administration in patients with preclinical diastolic dysfunction (PDD). BACKGROUND: PDD is characterized by normal systolic function and moderate or severe diastolic dysfunction but no symptoms of heart failure (HF). Impairment in cardiorenal endocrine response to stress by AVL exists in PDD and is corrected by acute administration of subcutaneous BNP. METHODS: A double-blinded, placebo-controlled proof-of-concept study was conducted to compare 12 weeks of twice daily subcutaneous BNP, 10 μg/kg (n = 24), versus placebo (n = 12) in PDD. Subjects underwent 2 study visits, at baseline and after 12 weeks. At each study visit, echocardiography, renal, and neurohumoral assessments were performed before and after intravascular AVL. RESULTS: Among those with PDD, there was a statistically significant improvement in diastolic function after 12 weeks of BNP, as measured by a decrease in the Doppler E/e' ratio (where E is early mitral inflow velocity and e' is mitral annulus early diastolic motion) (p = 0.004) and improvement of diastolic dysfunction grade (p = 0.008). After 12 weeks, there was statistically significantly greater sodium excretion, urine flow, and urinary cyclic guanosine monophosphate excretion to AVL (all p < 0.001), as well as a trend toward greater glomerular filtration rate (p = 0.050) in the BNP group as compared to the placebo group. CONCLUSIONS: In subjects with PDD, chronic BNP administration resulted in sustained improvement in diastolic function without development of tachyphylaxis to the enhancement of cardiorenal response to volume expansion with BNP. (Human Brain Natriuretic Peptide [BNP] [or Nesiritide] to Help Heart, Kidney and Humoral Function; NCT00405548).
RCT Entities:
OBJECTIVES: This study determined whether there is development of tachyphylaxis to enhancement of cardiorenal response to acute volume loading (AVL) with B-type natriuretic peptide (BNP) after 12-week, twice-daily subcutaneous BNP administration in patients with preclinical diastolic dysfunction (PDD). BACKGROUND:PDD is characterized by normal systolic function and moderate or severe diastolic dysfunction but no symptoms of heart failure (HF). Impairment in cardiorenal endocrine response to stress by AVL exists in PDD and is corrected by acute administration of subcutaneous BNP. METHODS: A double-blinded, placebo-controlled proof-of-concept study was conducted to compare 12 weeks of twice daily subcutaneous BNP, 10 μg/kg (n = 24), versus placebo (n = 12) in PDD. Subjects underwent 2 study visits, at baseline and after 12 weeks. At each study visit, echocardiography, renal, and neurohumoral assessments were performed before and after intravascular AVL. RESULTS: Among those with PDD, there was a statistically significant improvement in diastolic function after 12 weeks of BNP, as measured by a decrease in the Doppler E/e' ratio (where E is early mitral inflow velocity and e' is mitral annulus early diastolic motion) (p = 0.004) and improvement of diastolic dysfunction grade (p = 0.008). After 12 weeks, there was statistically significantly greater sodium excretion, urine flow, and urinary cyclic guanosine monophosphate excretion to AVL (all p < 0.001), as well as a trend toward greater glomerular filtration rate (p = 0.050) in the BNP group as compared to the placebo group. CONCLUSIONS: In subjects with PDD, chronic BNP administration resulted in sustained improvement in diastolic function without development of tachyphylaxis to the enhancement of cardiorenal response to volume expansion with BNP. (HumanBrain Natriuretic Peptide [BNP] [or Nesiritide] to Help Heart, Kidney and Humoral Function; NCT00405548).
Authors: Michael H Picard; David Adams; S Michelle Bierig; John M Dent; Pamela S Douglas; Linda D Gillam; Andrew M Keller; David J Malenka; Frederick A Masoudi; Marti McCulloch; Patricia A Pellikka; Priscilla J Peters; Raymond F Stainback; G Monet Strachan; William A Zoghbi Journal: J Am Soc Echocardiogr Date: 2011-01 Impact factor: 5.251
Authors: Adriaan A Voors; Mauro Gori; Licette C Y Liu; Brian Claggett; Michael R Zile; Burkert Pieske; John J V McMurray; Milton Packer; Victor Shi; Martin P Lefkowitz; Scott D Solomon Journal: Eur J Heart Fail Date: 2015-02-06 Impact factor: 15.534
Authors: Garvan C Kane; Barry L Karon; Douglas W Mahoney; Margaret M Redfield; Veronique L Roger; John C Burnett; Steven J Jacobsen; Richard J Rodeheffer Journal: JAMA Date: 2011-08-24 Impact factor: 56.272
Authors: Scott D Solomon; Michael Zile; Burkert Pieske; Adriaan Voors; Amil Shah; Elisabeth Kraigher-Krainer; Victor Shi; Toni Bransford; Madoka Takeuchi; Jianjian Gong; Martin Lefkowitz; Milton Packer; John J V McMurray Journal: Lancet Date: 2012-08-26 Impact factor: 79.321
Authors: Laura M G Meems; Ingrid A Andersen; Shuchong Pan; Gail Harty; Yang Chen; Ye Zheng; Gerald E Harders; Tomoki Ichiki; Denise M Heublein; Seethalakshmi R Iyer; S Jeson Sangaralingham; Daniel J McCormick; John C Burnett Journal: Hypertension Date: 2019-04 Impact factor: 9.897
Authors: Anja Glöde; Jennifer Naumann; Thorsten Gnad; Valentina Cannone; Ana Kilic; John C Burnett; Alexander Pfeifer Journal: Mol Metab Date: 2017-01-04 Impact factor: 7.422
Authors: Rika Kawakami; Candace Y W Lee; Christopher Scott; Kent R Bailey; John A Schirger; Horng H Chen; Sherry L Benike; Valentina Cannone; Fernando L Martin; S Jeson Sangaralingham; Tomoko Ichiki; John C Burnett Journal: Clin Pharmacol Ther Date: 2018-01-11 Impact factor: 6.875
Authors: Felix Hohendanner; Daniel Messroghli; David Bode; Florian Blaschke; Abdul Parwani; Leif-Hendrik Boldt; Frank R Heinzel Journal: ESC Heart Fail Date: 2018-02-19
Authors: Siu-Hin Wan; Isabel Torres-Courchoud; Paul M McKie; Joshua P Slusser; Margaret M Redfield; John C Burnett; David O Hodge; Horng H Chen Journal: JACC Basic Transl Sci Date: 2019-12-23